News
PHIO
--
0.00%
--
Phio Pharmaceuticals Closes $14 Million Private Placement of Almost 4.6 Million Shares
MT Newswires · 11h ago
Phio Pharma announces $14M private placement priced at-the-market
Phio Pharma ([[PHIO]] -5.5%) announces that it has entered into securities purchase agreements with certain institutional and accredited investors to raise about $14M.The company aims to raise the funds through
Seekingalpha · 4d ago
Phio Pharmaceuticals Announces $14.0 Million Private Placement Priced At-the-Market
MARLBOROUGH, Mass., Jan. 21, 2021 /PRNewswire via COMTEX/ -- MARLBOROUGH, Mass., Jan. 21, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a...
PR Newswire - PRF · 4d ago
Phio Pharmaceuticals Announces $14.0 Million Private Placement Priced At-the-Market
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it has entered into securi...
PR Newswire · 4d ago
Phio Pharmaceuticals to Participate in the H.C. Wainwright BioConnect 2021 Conference
, /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its Chi...
PR Newswire - PRF · 01/04 21:15
Phio Pharmaceuticals to Participate in the H.C. Wainwright BioConnect 2021 Conference
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its Chief Executive Office...
PR Newswire · 01/04 21:15
Thinking about buying stock in Immersion Corp, IRIDEX Corp, One Stop Systems, Phio Pharmaceuticals, or Alkermes?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IMMR, IRIX, OSS, PHIO, and ALKS.
PR Newswire - PRF · 12/29/2020 14:38
EH, GEVO, NNDM and BEST among premarket gainers
Universal Security Instruments (UUU) +293%.Technical Communications (TCCO) +214%.Koss Corporation (KOSS) +99%.Tenax Therapeutics (TENX) +80%.New Concept Energy (GBR) +58%.IRIDEX Corporation (IRIX) +23%.SOS Limited (SOS) +10% after announcing partnership with Zhonglu P&C Insurance.Immersion Corporation
Seekingalpha · 12/29/2020 13:19
Phio Pharmaceuticals Issued U.S Patent 10,876,119 'Reduced size self-delivering RNAI compounds'
Phio Pharmaceuticals Issued U.S Patent 10,876,119 'Reduced size self-delivering RNAI compounds'
Benzinga · 12/29/2020 10:37
Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference
, /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its chief executive officer, Dr. Gerrit Dispersyn, will present at the upcoming 3rd Annual Evercore ISI HealthCONx Conference, which is being held virtually this year from .
PR Newswire - PRF · 11/19/2020 12:30
Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference
, /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its chi...
PR Newswire - PRF · 11/19/2020 12:30
Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its chief executive office...
PR Newswire · 11/19/2020 12:30
Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its chief executive officer, Dr. Gerrit Dispersyn, will present at the upcoming 3rd Annual Evercore ISI HealthCONx Conference, which is being held virtually this year from December 1-3, 2020.
PR Newswire · 11/19/2020 12:30
Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update
, /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial...
PR Newswire - PRF · 11/10/2020 22:00
Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update
, /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the quarter ended and provided a business update.
PR Newswire - PRF · 11/10/2020 22:00
Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the qu...
PR Newswire · 11/10/2020 22:00
Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment
, /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced positive dat...
PR Newswire - PRF · 11/09/2020 13:00
Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment
, /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced positive data from an study that shows the strong antitumoral efficacy of individual INTASYL pipeline products, including PH-762, PH-790 and PH-804, can be further improved by combining them in a single therapeutic. These data were presented during The Society for Immunotherapy of Cancer (SITC) 35 Anniversary Annual Meeting - Abstract 198: "Combination intratumoral treatment with INTASYL™ self-delivering RNAi targeting TIGIT and PD-1/PD-L1 improves tumor control compared to monotherapy in a CT26 model of murine colorectal cancer ".
PR Newswire - PRF · 11/09/2020 13:00
Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment
PR Newswire · 11/09/2020 13:00
Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced positive data from an in vivo s...
PR Newswire · 11/09/2020 13:00
Webull provides a variety of real-time PHIO stock news. You can receive the latest news about Phio Pharmaceuticals Corp through multiple platforms. This information may help you make smarter investment decisions.
About PHIO
Phio Pharmaceuticals Corp, formerly RXi Pharmaceuticals Corporation, is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) (sd-rxRNA) therapeutic platform. The Company’s focuses on developing sd-rxRNA therapeutic compounds to be used in the context of adoptive cell transfer by targeting checkpoints or other gene targets, or to be used in immunotherapy following intratumoral injection. The Company’s pipeline include RXI-762 and RXI-804. Its sd-rxRNA compounds are designed to down-regulate the expression of a specific gene that may be over-expressed in a disease condition. The Company is developing RXI-762 for the treatment of Melanoma, Ovarian cancer and other indications. RXI-804 is an sd-rxRNA compound that is designed to suppress the expression of immune checkpoint protein, TIGIT.
More